Clinical Trial Results: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult Hodgkin and non…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Relatlimab (relatlimab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Lymphoma, Non-Hodgkin, Hodgkin Disease | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-06-26